AU2013229274A1 - Pharmaceutical antiretroviral combinations comprising lamivudine, festinavir and nevirapine - Google Patents
Pharmaceutical antiretroviral combinations comprising lamivudine, festinavir and nevirapine Download PDFInfo
- Publication number
- AU2013229274A1 AU2013229274A1 AU2013229274A AU2013229274A AU2013229274A1 AU 2013229274 A1 AU2013229274 A1 AU 2013229274A1 AU 2013229274 A AU2013229274 A AU 2013229274A AU 2013229274 A AU2013229274 A AU 2013229274A AU 2013229274 A1 AU2013229274 A1 AU 2013229274A1
- Authority
- AU
- Australia
- Prior art keywords
- nevirapine
- pharmaceutical
- composition according
- lamivudine
- festinavir
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN583MU2012 | 2012-03-05 | ||
| IN583/MUM/2012 | 2012-03-05 | ||
| PCT/GB2013/000092 WO2013132208A1 (en) | 2012-03-05 | 2013-03-05 | Pharmaceutical antiretroviral combinations comprising lamivudine, festinavir and nevirapine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2013229274A1 true AU2013229274A1 (en) | 2014-09-04 |
Family
ID=47884388
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2013229274A Abandoned AU2013229274A1 (en) | 2012-03-05 | 2013-03-05 | Pharmaceutical antiretroviral combinations comprising lamivudine, festinavir and nevirapine |
Country Status (13)
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9688666B2 (en) * | 2013-02-07 | 2017-06-27 | Tobira Therapeutics, Inc. | Lamivudine salts |
| EP3153157A1 (en) | 2015-10-09 | 2017-04-12 | Teva Pharmaceutical Works Private Limited Company | Pharmaceutical composition for prolonged release of nevirapine |
| TW202024061A (zh) | 2017-08-17 | 2020-07-01 | 美商基利科學股份有限公司 | Hiv蛋白質膜抑制劑之固體形式 |
| AR112412A1 (es) | 2017-08-17 | 2019-10-23 | Gilead Sciences Inc | Formas de sal de colina de un inhibidor de la cápside del vih |
| WO2019161017A1 (en) | 2018-02-15 | 2019-08-22 | Gilead Sciences, Inc. | Pyridine derivatives and their use for treating hiv infection |
| CA3103522C (en) | 2018-07-16 | 2023-11-21 | Gilead Sciences, Inc. | Capsid inhibitors for the treatment of hiv |
| MX2021008751A (es) | 2019-01-25 | 2021-11-12 | Univ Brown | Composiciones y metodos para tratar, prevenir o revertir la inflamacion y los trastornos asociados a la edad. |
| TWI858267B (zh) | 2020-06-25 | 2024-10-11 | 美商基利科學股份有限公司 | 用於治療hiv之蛋白殼抑制劑 |
| AU2022403012B2 (en) | 2021-12-03 | 2026-02-12 | Gilead Sciences, Inc. | Therapeutic compounds for hiv virus infection |
| AU2022399845B2 (en) | 2021-12-03 | 2026-03-26 | Gilead Sciences, Inc. | Therapeutic compounds for hiv virus infection |
| FI4440702T3 (fi) | 2021-12-03 | 2025-08-08 | Gilead Sciences Inc | Terapeuttisia yhdisteitä hiv-virusinfektiota varten |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE131730T1 (de) | 1991-05-16 | 1996-01-15 | Glaxo Group Ltd | Nukleosidanalogen enthaltende antiviren- zubereitungen |
| GB9622681D0 (en) | 1996-10-31 | 1997-01-08 | Glaxo Group Ltd | Pharmaceutical compositions |
| ES2172944T3 (es) * | 1997-12-05 | 2002-10-01 | Alza Corp | Forma de dosificacion osmotica que comprende un primer y un segundo revestimiento. |
| BR9906933A (pt) | 1998-01-16 | 2001-11-27 | Medivir Ab | Antiviróticos |
| GB9809213D0 (en) | 1998-04-29 | 1998-07-01 | Glaxo Group Ltd | Pharmaceutical compositions |
| EP1610797A1 (en) | 2003-03-27 | 2006-01-04 | Boehringer Ingelheim International GmbH | Antiviral combination of nevirapine and a further antiretroviral compound |
| KR20080053317A (ko) * | 2005-08-31 | 2008-06-12 | 씨아이피엘에이 엘티디. | 라미부딘, 스타부딘 및 네비라핀을 포함하는 약학적 조합물 |
| AU2008262031B2 (en) * | 2007-06-08 | 2011-08-25 | Boehringer Ingelheim International Gmbh | Extended release formulation of nevirapine |
-
2013
- 2013-03-05 CA CA2866133A patent/CA2866133A1/en not_active Abandoned
- 2013-03-05 MX MX2014010337A patent/MX2014010337A/es unknown
- 2013-03-05 AU AU2013229274A patent/AU2013229274A1/en not_active Abandoned
- 2013-03-05 US US14/382,444 patent/US20150104511A1/en not_active Abandoned
- 2013-03-05 BR BR112014021927A patent/BR112014021927A2/pt not_active IP Right Cessation
- 2013-03-05 RU RU2014140177A patent/RU2014140177A/ru not_active Application Discontinuation
- 2013-03-05 KR KR20147027819A patent/KR20140138837A/ko not_active Withdrawn
- 2013-03-05 IN IN1907MUN2014 patent/IN2014MN01907A/en unknown
- 2013-03-05 JP JP2014560438A patent/JP2015509524A/ja active Pending
- 2013-03-05 EP EP13709491.8A patent/EP2822560A1/en not_active Withdrawn
- 2013-03-05 CN CN201380012366.4A patent/CN104203244A/zh active Pending
- 2013-03-05 WO PCT/GB2013/000092 patent/WO2013132208A1/en not_active Ceased
-
2014
- 2014-09-04 ZA ZA2014/06495A patent/ZA201406495B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA201406495B (en) | 2016-03-30 |
| BR112014021927A2 (pt) | 2019-09-24 |
| WO2013132208A8 (en) | 2013-11-07 |
| MX2014010337A (es) | 2014-11-14 |
| KR20140138837A (ko) | 2014-12-04 |
| EP2822560A1 (en) | 2015-01-14 |
| JP2015509524A (ja) | 2015-03-30 |
| RU2014140177A (ru) | 2016-04-27 |
| IN2014MN01907A (cg-RX-API-DMAC10.html) | 2015-07-10 |
| US20150104511A1 (en) | 2015-04-16 |
| CA2866133A1 (en) | 2013-09-12 |
| WO2013132208A1 (en) | 2013-09-12 |
| CN104203244A (zh) | 2014-12-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2822560A1 (en) | Pharmaceutical antiretroviral combinations comprising lamivudine, festinavir and nevirapine | |
| AU2013336491B2 (en) | Pharmaceutical antiretroviral composition | |
| WO2014184553A1 (en) | Pharmaceutical antiretroviral compositions | |
| US20070059360A1 (en) | Water-dispersible anti-retroviral pharmaceutical compositions | |
| AU2012264475A1 (en) | Pharmaceutical antiretroviral composition | |
| TW201622731A (zh) | 包含恩曲他濱（Ｅｍｔｒｉｃｉｔａｂｉｎｅ）、替諾福韋（Ｔｅｎｏｆｏｖｉｒ）、地瑞那韋（Ｄａｒｕｎａｖｉｒ）及利托那韋（Ｒｉｔｏｎａｖｉｒ）之單位劑型以及包含地瑞那韋及利托那韋之單層錠劑 | |
| MXPA06006586A (es) | Metodos de dosificacion para la terapia antiviral con beta-d-2',3'-didesoxi-2',3'-dideshidro-5-fluorocitidina. | |
| TW201511780A (zh) | 抗病毒化合物之固體分散調合物 | |
| WO2013057469A1 (en) | Pharmaceutical antiretroviral compositions | |
| CN114642639A (zh) | 一种枸橼酸托法替布缓释组合物及其制备方法 | |
| WO2009106954A1 (en) | Stable dosage forms of lamivudine and tenofovir | |
| TW200911303A (en) | Powders for reconstitution | |
| US20160199396A1 (en) | Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir and a monolithic tablet comprising darunavir and ritonavir | |
| US20090088424A1 (en) | Methods and compositions for controlling the bioavailability of poorly soluble drugs | |
| TW201542212A (zh) | 包括恩曲他濱、泰諾福韋、地瑞那韋與利托那韋的單位劑量形式以及包括地瑞那韋與利托那韋的單體錠劑 | |
| WO2009037449A1 (en) | Solid pharmaceutical compositions comprising one or more herpes virus inhibitors and one or more reverse transcriptase inhibitors | |
| EP2844231A1 (en) | Antiretroviral composition | |
| EP3334419A1 (en) | Solid pharmaceutical composition of abacavir, lamivudine, and efavirenz | |
| WO2018028841A1 (en) | Solid pharmaceutical composition of abacavir, lamivudine, and efavirenz | |
| WO2018064071A1 (en) | Therapeutic compositions for treatment of human immunodeficiency virus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |